[HTML][HTML] MEK and the inhibitors: from bench to bedside
A Akinleye, M Furqan, N Mukhi, P Ravella… - Journal of hematology & …, 2013 - Springer
A Akinleye, M Furqan, N Mukhi, P Ravella, D Liu
Journal of hematology & oncology, 2013•SpringerFour distinct MAP kinase signaling pathways involving 7 MEK enzymes have been
identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK
inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of
metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in
combination with docetaxel in phase II randomized trial in previously treated patients with
advanced lung cancer. Selumetinib group had better response rate and progression-free …
identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK
inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of
metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in
combination with docetaxel in phase II randomized trial in previously treated patients with
advanced lung cancer. Selumetinib group had better response rate and progression-free …
Abstract
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.
Springer